| Over the past decade, investing in biotech stocks with insider buying has tripled the S&P 500's return. Tandem Diabetes Care (Nasdaq: TNDM) and Exscientia PLC (Nasdaq: EXAI) are prime examples of some I've recommended. The former was a particularly big winner, allowing my readers to lock in up to a 1,795% gain in less than one year. Needless to say, I'm bullish on the industry. But there's one big problem faced by most biotechs: Drug discovery. More specifically, how long drug discovery takes and how much it costs. Drug discovery hasn't changed much in the last century. It still takes up to a decade or even more in some cases to develop a new drug. It's a long, manual process with lots of trial and error (not to mention government red tape) that can be performed only by highly trained resources. Because of that, it's also astronomically expensive. The average cost to develop a new drug is $2.6 billion... That's a lot of money to shell out for a drug that may not even make the cut - a full 9 out of 10 drugs entering Phase 1 clinical trials never make it to market. They get shot down by the Food and Drug Administration (FDA), often for good reason. But by that point, it's already cost billions of dollars to develop them. That's changing, though. And it's changing fast. Artificial intelligence (AI) can make drug development a faster and cheaper process with fewer costly failures. It can shorten drug development times from a decade-plus on average to just a few short years and give us better, longer, healthier lives in the process. I recently found a company that is using AI to support the entire biotech industry. Because, unlike many biotech companies that focus on only one specific segment of the drug development process, this company helps other biotechs make new breakout discoveries. In fact, it has supported 80% of all FDA-approved novel drugs that have hit the market over the past five years. If you're taking a new drug, there's a good chance this company helped develop it. I'm expecting big things for this company because its insiders are piling in at a breakneck pace... I think the biggest growth is just on the horizon. That's based on the fact that insiders have loaded up on $1.45 million worth of shares in the last 12 months - with some of the fastest buying happening as we were coming into the end of 2023. Among the biggest purchases were those from the CEO, who bought 5,620 shares for just over $1 million, and the COO, who bought 1,322 shares for just under $250,000 - both in November 2023. That's a prime example of the cluster buying that I look for - and from two of the highest-ranking executives at the company to boot... And when I see high-level insiders plunk down big money on their own stocks, I know something big is likely to happen soon... | 
Tidak ada komentar:
Posting Komentar